Floatz logo

MITOMYCIN C

Pseudomyxoma Peritonei

Albert Einstein College of MedicineSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Pseudomyxoma Peritonei cohort.

Asset / SponsorPhaseRating
Irinotecan
Stony Brook University
Phase 2BB
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Carboplatin
Case Comprehensive Cancer Center
Phase 1CC
Sgn-Stnv
Seagen Inc.
Phase 1CC

Same molecule, other indications

MITOMYCIN C is also rated in:

colorectal carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
appendix carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
peritoneal carcinomatosisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →